Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End‐Stage Kidney Disease
Open Access
- 7 July 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 9 (13), e015969
- https://doi.org/10.1161/jaha.120.015969
Abstract
Background The rate of sudden cardiac death in the hemodialysis population exceeds that of the general population by >20‐fold. Hemodialysis patients may be particularly susceptible to sudden cardiac death provoked by drug‐induced QT prolongation because of their substantial cardiovascular disease burden, exposure to electrolyte shifts during dialysis, and extensive polypharmacy. However, population‐specific data regarding the frequency and patterns of QT prolonging medication use are limited. Methods and Results We conducted a descriptive drug utilization study using 3 administrative databases, the United States Renal Data System, MarketScan, and Medicare claims. We characterized the extent and patterns of QT prolonging medication use by adult hemodialysis patients and individuals without end‐stage kidney disease annually from 2012 to 2016. We also identified instances of high‐risk QT prolonging medication use among hemodialysis patients. In total, 338 515 hemodialysis patients and 40.7 million individuals without end‐stage kidney disease were studied. Annual utilization rates of QT prolonging medications with known torsades de pointes risk in hemodialysis patients were ~1.4 to ~2.5 times higher than utilization rates in individuals without end‐stage kidney disease. Hemodialysis patients with demographic and clinical risk factors for drug‐induced QT prolongation were exposed to medications with known torsades de pointes risk more often than patients without risk factors. Conclusions Hemodialysis patients use QT prolonging medications with known torsades de pointes risk more extensively than individuals without end‐stage kidney disease. Given the widespread use and instances of high‐risk prescribing, future studies evaluating the cardiac safety of these drugs in the hemodialysis population are needed.Keywords
This publication has 32 references indexed in Scilit:
- Stratification for Confounding – Part 2: Direct and Indirect StandardizationNephron Clinical Practice, 2010
- Prevention of Torsade de Pointes in Hospital SettingsCirculation, 2010
- Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation Endorsed by the American Association of Critical-Care Nurses and the International Society for Computerized ElectrocardiologyJournal of the American College of Cardiology, 2010
- Patterns of Late Gadolinium Enhancement in Chronic Hemodialysis PatientsJACC: Cardiovascular Imaging, 2008
- The Challenge of Sudden Death in Dialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imagingKidney International, 2006
- Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac deathEuropean Heart Journal, 2005
- Torsade de Pointes Due to Noncardiac DrugsMedicine, 2003
- Knowledge Deficits Related to the QT Interval Could Affect Patient SafetyAnnals of Noninvasive Electrocardiology, 2003
- Pharmacology of DiureticsThe American Journal of the Medical Sciences, 2000